Alexion Pharm Inc (ALXN) 123.98 $ALXN Biotech Stock

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 1:23 PM

Alexion Pharm Inc (ALXN) 123.98 $ALXN

Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 76.95 (-0.47), ALXN: 123.98 (-1.65), MYL: 40.35 (-1.57), AMGN: 169.23 (-0.90), ARIA: 10.06 (-0.13), RIGL: 3.37 (-0.08), REGN: 387.89 (-5.51)

After Yesterday's Decline of 1.73%, Alexion Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Wed Aug 31, 2:13PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $125.69 to a high of $128.72. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $127.28 on volume of 465,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 123.98 (-1.65)

Biotech Stocks on Investors' Radar -- Alexion Pharma, BioMarin Pharma, Merrimack Pharma, and Pacific Biosciences of California
PR Newswire - Wed Aug 31, 6:50AM CDT
Stock-Callers.com's focus shifted to Biotechnology industry which uses biological systems or living organisms for the development of biopharmaceutical drugs. Two main catalysts driving stocks in this arena are clinical and regulatory developments. Let us now review today's featured companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Learn more about these stocks by downloading their comprehensive and free reports at:
MACK: 4.54 (-0.05), PACB: 8.21 (-0.09), BMRN: 95.75 (+0.56), ALXN: 123.98 (-1.65)

Alexion's GVHD Candidate Gets Orphan Drug Status in the EU
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:04AM CDT
Alexion Pharmaceuticals' (ALXN) ALXN1007 received orphan drug designation in the EU for the treatment of graft-versus-host disease.
ANIP: 60.17 (-1.25), GERN: 2.75 (+0.02), ALXN: 123.98 (-1.65), ANIK: 47.73 (-0.21)

European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)
BusinessWire - Mon Aug 29, 3:33PM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to ALXN1007, a novel anti-inflammatory monoclonal antibody targeting complement protein C5a, for the treatment of graft-versus-host disease (GVHD). Alexion is currently investigating ALXN1007 in patients with acute GVHD of the lower gastrointestinal tract (GI-GVHD), a severe and life-threatening rare autoimmune disease that can occur as a complication of stem cell or bone marrow transplantation.(1,2,3)
ALXN: 123.98 (-1.65)

Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 80.87 (-0.06), BIIB: 312.79 (+6.76), PTLA: 20.76 (-0.10), CLVS: 23.16 (-0.43), GILD: 76.95 (-0.47), ALXN: 123.98 (-1.65), REGN: 387.89 (-5.51)

After Yesterday's Rally of 3.12% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 1:30PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $133.06 to a high of $136.26. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $134.43 on volume of 524,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 123.98 (-1.65)

New Strong Sell Stocks for August 22nd
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:33AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
SYT: 88.12 (+0.44), HSNI: 42.02 (+0.06), ALXN: 123.98 (-1.65), CBT: 50.44 (+0.41), WAGE: 63.70 (+0.92)

Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.44%
Comtex SmarTrend(R) - Mon Aug 15, 2:19PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $133.83 to a high of $136.70. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $135.49 on volume of 630,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 123.98 (-1.65)

New Strong Sell Stocks for August 15th
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 6:37AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
ACHC: 51.27 (+0.94), ABAX: 49.96 (-0.44), ARCB: 18.65 (+0.18), AV: 11.65 (+0.09), ALXN: 123.98 (-1.65)

Exxon Mobil and SolarCity skid; Caesars advances
AP - Mon Aug 01, 4:08PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
PN: 8.88 (+0.20), ALXN: 123.98 (-1.65), CZR: 6.26 (+0.03), FLTX: 59.87 (-0.02), IONS: 29.84 (-0.20), FDC: 14.34 (+0.41)

Look for Shares of Alexion Pharmaceuticals to Potentially Pullback after Yesterday's 3.06% Rise
Comtex SmarTrend(R) - Mon Aug 01, 12:23PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $128.76 to a high of $135.14. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $135.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 123.98 (-1.65)

After Yesterday's Rally of 1.96% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jul 28, 12:10PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $130.00 to a high of $135.00. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $130.32 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 123.98 (-1.65)

Alexion (ALXN) Tops Q2 Earnings and Revenues (Revised)
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 10:33AM CDT
Alexion's (ALXN) second-quarter 2016 earnings of 93 cents per share surpassed the Zacks Consensus Estimate of 91 cents.
INVA: 11.01 (-0.06), ANIP: 60.17 (-1.25), ALXN: 123.98 (-1.65), NKTR: 18.27 (+0.16)

Alexion (ALXN) Beats on Q2 Earnings and Revenues
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:15AM CDT
Alexion (ALXN) reported earnings of 92 cents in the second-quarter of 2016, with revenues coming in at $753 million.
ALXN: 123.98 (-1.65)

Alexion Reports Second Quarter 2016 Results
BusinessWire - Thu Jul 28, 5:30AM CDT
--- Soliris(R) (eculizumab) Revenue Growth Driven by Steady Number of New Patients with PNH and aHUS Treated Globally -
ALXN: 123.98 (-1.65)

Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 312.79 (+6.76), VRTX: 94.69 (-0.06), GILD: 76.95 (-0.47), ALXN: 123.98 (-1.65), AMGN: 169.23 (-0.90), ABBV: 64.02 (-0.01), CELG: 105.46 (-0.91)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Graywind Redefines Flexibility with New Blinds 2.0

Sliding blinds—who knew they'd stir up such a fuss? But here comes Graywind, rolling out their Manual Sliding Track Blinds 2.0, and it's clear they're turning heads in Santa Clara and beyond. This ain't your grandma's drapery setup. We're talking about a sleek, mid-to-premium panel-track system designed to cater to modern living spaces and architectural whimsy. It's...

Decoding Historic Home Buys: Tips for New Owners

Realities Behind the Rustic Facade Picture this: you’re standing in front of a crumbling beauty with crown molding and character oozing from its very walls. Now what? It's easy to get swept away by the allure of a historic home, but there's gritty work to be done under those charming facades. Enter Debi Beiland of Limestone Properties over in Maysville, KY. She’s got...

Fujifilm's New 400mm Lens: A Game Changer?

Big Moves from Fujifilm's Camp Now we're talking, Fujifilm! Just when you think they might ease off the throttle, they crank up the heat with the XF 400mm f/4.5 R LM OIS WR lens. This isn’t just your run-of-the-mill update. It's a significant addition to their already beefed-up lineup for sports and wildlife. You know what that means: more reach, less baggage. Compact...

Eyepic 2-in-1 Camera Innovates at IFA 2026

Call me a sucker for new tech but what Hohem just unveiled might flip content creation on its head. Welcome the Eyepic—a 2-in-1 pocket gimbal camera stirring things up at IFA 2026 in Berlin. Now, maybe your eyeballs are glazing over with all the camera announcements flooding the market. I get it. Yet, this gadget isn’t just another add-on; it's a sneaky move by Hohem...

EF English Live's Approach to Workplace Confidence

Pioneering English Confidence for the Global Workplace Stepping into a meeting with international partners requires more than just textbook knowledge of English. It's about confidently expressing ideas, adapting on the fly, and engaging with global colleagues. Enter EF English Live, a leader in transforming workplace communication through targeted English learning. Expert...

October 15 Marks Prologis Q3 2026 Results Call

Prologis Steps Up to the Plate This October If you’ve got a finger in any logistic pies, make sure it's wrapped around the latest from Prologis come October 15. The logistics behemoth is rolling out the red carpet for its third quarter results, with all eyes on what their senior management will spill. Frankly, you don’t just show up to these things to sip coffee and...

Argo Biopharma's BW-20805 Shows Promise in HAE Phase II Trial

Argo's Gains in Hereditary Angioedema Therapy Think about it, folks – reducing a hereditary angioedema attack by over 80%? Argo Biopharma, the slick operator in the RNA therapeutics space, is flexing its muscles again. They've hauled in some impressive data for their siRNA therapeutic, BW-20805, at the 2026 Bradykinin Symposium in Berlin. For you deep-pocketed investors...

Restaurant Industry Bolsters Safety with New Guide

There’s a fresh playbook hitting the shelves, and it’s aimed at the heart of the dining world—a guide that tackles the nasty curveballs of public safety incidents. Restaurants, the places we count on for warm meals and cold drinks, aren’t just about what’s on the menu; they're about keeping folks safe, too. The National Restaurant Association just dropped a new...

CAPR Faces Lawsuit and FDA Delay: Investor Alert

Trouble Brewin' for Capricor Investors Buckle up, folks. Capricor Therapeutics (NASDAQ: CAPR) is caught in a storm, facing not just the lengthy arm of law with a securities class action, but also a seemingly endless wait with the FDA's decision on their lead product. We're talking serious implications for anyone with skin in the game. The FDA's Delayed Blessing So the...

PinkBlush Maternity Unveils Its 2026 Fall Fashion Line

Elevating Maternity Fashion with PinkBlush's Fall 2026 Line You know, it's not every day you see maternitywear aiming to push the envelope, but that's exactly what PinkBlush is doing this fall. They've unleashed their Fall 2026 collection, and let's just say, it's less about the frills and more about redefining what expecting mothers can expect from the fashion world. A...